
## Emily C Baechler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11377520/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2610-2615.	7.1	1,978
2	Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nature Genetics, 2008, 40, 204-210.	21.4	1,192
3	A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nature Genetics, 2009, 41, 1228-1233.	21.4	729
4	A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nature Genetics, 2006, 38, 550-555.	21.4	593
5	Genetic Association of the R620W Polymorphism of Protein Tyrosine Phosphatase PTPN22 with Human SLE. American Journal of Human Genetics, 2004, 75, 504-507.	6.2	591
6	Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6758-6763.	7.1	428
7	Elevated Serum Levels of Interferon-Regulated Chemokines Are Biomarkers for Active Human Systemic Lupus Erythematosus. PLoS Medicine, 2006, 3, e491.	8.4	262
8	An Interferon Signature in the Peripheral Blood of Dermatomyositis Patients is Associated with Disease Activity. Molecular Medicine, 2007, 13, 59-68.	4.4	262
9	Interferonâ€regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study. Arthritis and Rheumatism, 2009, 60, 3098-3107.	6.7	251
10	The emerging role of interferon in human systemic lupus erythematosus. Current Opinion in Immunology, 2004, 16, 801-807.	5.5	208
11	Interleukinâ€6 and type I interferon–regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis and Rheumatism, 2009, 60, 3436-3446.	6.7	198
12	Visualizing Human Leukocyte Antigen Class II Risk Haplotypes in Human Systemic Lupus Erythematosus. American Journal of Human Genetics, 2002, 71, 543-553.	6.2	197
13	<i>Ebf1</i> or <i>Pax5</i> haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. Journal of Experimental Medicine, 2011, 208, 1135-1149.	8.5	140
14	Microarray Analyses of Peripheral Blood Cells Identifies Unique Gene Expression Signature in Psoriatic Arthritis. Molecular Medicine, 2005, 11, 21-29.	4.4	113
15	Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Research and Therapy, 2011, 13, 249.	3.5	106
16	On silico peptide microarrays for high-resolution mapping of antibody epitopes and diverse protein-protein interactions. Nature Medicine, 2012, 18, 1434-1440.	30.7	97
17	Gene expression profiling in human autoimmunity. Immunological Reviews, 2006, 210, 120-137.	6.0	92
18	Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus. Journal of Clinical Investigation, 2013, 123, 5135-5145.	8.2	92

EMILY C BAECHLER

#	Article	IF	CITATIONS
19	Genetic linkage and transmission disequilibrium of marker haplotypes at chromosome 1q41 in human systemic lupus erythematosus. Arthritis Research, 2001, 3, 299.	2.0	41
20	Primary EBV Infection Induces an Expression Profile Distinct from Other Viruses but Similar to Hemophagocytic Syndromes. PLoS ONE, 2014, 9, e85422.	2.5	41
21	Gene-expression profiling in rheumatic disease: tools and therapeutic potential. Nature Reviews Rheumatology, 2009, 5, 257-265.	8.0	37
22	PTPN22 Variant R620W Is Associated With Reduced Tollâ€ <b>i</b> ike Receptor 7–Induced Type I Interferon in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2015, 67, 2403-2414.	5.6	37
23	Multiplex giant magnetoresistive biosensor microarrays identify interferon-associated autoantibodies in systemic lupus erythematosus. Scientific Reports, 2016, 6, 27623.	3.3	30
24	Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis. Journal of Rheumatology, 2017, 44, 117-124.	2.0	25
25	High-Resolution Analysis of Antibodies to Post-Translational Modifications Using Peptide Nanosensor Microarrays. ACS Nano, 2016, 10, 10652-10660.	14.6	21
26	Adipokine gene expression in peripheral blood of adult and juvenile dermatomyositis patients and their relation to clinical parameters and disease activity measures. Journal of Inflammation, 2015, 12, 29.	3.4	16
27	The Use of Microarrays to Study Autoimmunity. Journal of Investigative Dermatology Symposium Proceedings, 2004, 9, 18-22.	0.8	13
28	Progress towards Understanding the Genetic Pathogenesis of Systemic Lupus Erythematosus. Novartis Foundation Symposium, 2008, 267, 145-164.	1.1	13
29	Mapping epitopes of U1-70K autoantibodies at single-amino acid resolution. Autoimmunity, 2015, 48, 513-523.	2.6	11
30	Interferon Chemokine Score and Other Cytokine Measures Track With Changes in Disease Activity in Patients With Juvenile and Adult Dermatomyositis. ACR Open Rheumatology, 2019, 1, 83-89.	2.1	10
31	Using Gene Expression to Improve the Power of Genome-Wide Association Analysis. Human Heredity, 2014, 78, 94-103.	0.8	8
32	Defining a new molecular basis of systemic lupus erythematosus through transcriptional profiling. Expert Review of Clinical Immunology, 2007, 3, 913-923.	3.0	1
33	Increased expression of ADAMTS13 mRNA correlates with ischemic cerebrovascular disease in systemic lupus erythematosus patients. SAGE Open Medicine, 2013, 1, 205031211351440.	1.8	1
34	<i>Ebf1</i> or <i>Pax5</i> haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. Journal of Cell Biology, 2011, 193, i13-i13.	5.2	0